Does anyone know when the $36.9m in TD investments matured? 183 days since the CR would suggests to me that this would simply be held as additional cash now, or a portion rolled over and reinvested, but nothing in the accounts in this regard. What are investors' thoughts on the cash levels to see us through this year's R&D and admin expenditure? Anyone expect cost increases of any significance in ramping up CANVAS clinical trials during 2012? $4.1m Saxony grant for European trials nice to have tucked away and ready.
half yearly report, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16911 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 154170 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |